Clinical trials: Advanced Cancer
Advanced Endstage Solid Carcinomas in Adults
CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors
To assess the anti-tumor activity of CAP7.1 based on the observed objective response rate and rate of disease stabilization, as defined by the below primary and secondary endpoints, in patients with Non-Small Cell Lung Carcinoma…
- Trial name
- CAP7-1 (NCT02094560)
- Testing
- CAP7.1
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- CellAct Pharma GmbH
Breast Cancer
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
Primary Objective(s): To compare the activity (progression-free survival [PFS]) of anastrozole in combination with lonafarnib to that of anastrozole in combination with placebo in subjects with hormone-sensitive ADVANCED breast…
- Trial name
- NCT00081510
- Testing
- Lonafarnib, anastrozole
- Volunteers
- 110 people
- Sponsor
- Merck Sharp & Dohme LLC
Sarcoma, Soft Tissue Sarcoma
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT04906876
- Testing
- Gemcitabine, Docetaxel, 9-ING-41
- Where
- 2 sites in United States
- Sponsor
- Brown University
Metastatic Soft-tissue Sarcoma
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
To find a recommended dose of attIL2-TIL cell therapy that can be given to participant with either relapsed or metastatic sarcomas (has come back or spread to other parts of the body, respectively).
- Trial name
- NCT06474676
- Testing
- Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Hematologic Malignancy
GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Immune checkpoint blockade has made great but unsatisfied success in treating cancers. One important reason is the hijacked HLA (Human Leukocyte Antigen) antigen presentation.
- Trial name
- NCT04944888
- Testing
- Eliglustat, Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Chinese PLA General Hospital
Peritoneal Neoplasms, Retroperitoneal Neoplasms
Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer
There has been no successful treatment of diffuse peritoneal metastasis or carcinomatosis, in childhood tumors. Once this advanced stage of disease is evident, survival is measured in weeks.
- Conditions
- Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma
- Trial name
- NCT00436657
- Testing
- CHPP of Cisplatin, Abdominal Surgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamous Cell Carcinoma (ESCC), Infiltration
Infiltration Pattern of Locally Advanced ESCC
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Infiltration, Tumour
- Trial name
- NCT07567716
- Testing
- Esophagectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Colorectal Neoplasms, Lung Neoplasms
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
- Conditions
- Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00976508
- Testing
- figitumumab, pegvisomant
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive
- Trial name
- NCT02529813
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Biphenotypic Leukemia, Acute Leukemia
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hairy Cell Leukemia
- Trial name
- NCT03739606
- Testing
- Anti-CD123/CD3 Monoclonal Antibody MGD006
- Sponsor
- City of Hope Medical Center
Neuroblastoma
GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.
This exploratory clinical study will evaluate the efficacy and feasibility of combining a GSL synthase inhibitor with a granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with advanced or metastatic…
- Trial name
- NCT07090538
- Testing
- Eliglustat
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Lymphoma
Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells.
- Trial name
- NCT00002618
- Testing
- filgrastim, cytarabine, doxorubicin hydrochloride
- Where
- 10 sites in United States, Puerto Rico and 1 more
- Volunteers
- 242 people
- Sponsor
- Children's Oncology Group
Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
This study is a prospective, single center, phase II clinical study involving 108 patients with primary and late stage Diffuse Large B-cell Lymphoma complicated by large masses and extranodal involvement.
- Conditions
- Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy
- Trial name
- NCT05874778
- Testing
- 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy, Radiotherapy beyond standard R-CHOP Chemotherapy
- Volunteers
- 108 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Endometrial Cancer, Psychosocial Effects of Cancer and Its Treatment
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002493
- Testing
- cisplatin, doxorubicin hydrochloride, low-LET photon therapy
- Where
- 58 sites in United States
- Sponsor
- Gynecologic Oncology Group
Penile Cancer
Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Combining irinotecan with cisplatin may kill more tumor cells.
- Trial name
- NCT00066391
- Testing
- cisplatin, irinotecan hydrochloride, neoadjuvant therapy
- Where
- 8 sites in Belgium, France and 4 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Extranodal NK/T-cell Lymphoma
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine, pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients
- Trial name
- NCT04917250
- Testing
- Gemcitabine, Pegaspargase, Etoposide
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Tongren Hospital
Prostate Cancer
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival.
- Trial name
- FAST-NL (NCT01215526)
- Where
- 47 sites in Netherlands
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Graft Versus Host Disease, Leukemia
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
RATIONALE: Giving chemotherapy, such as clofarabine, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00423514
- Testing
- filgrastim, clofarabine, melphalan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage III or stage IV melanoma that cannot be…
- Trial name
- NCT00089206
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Virginia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.